Gonadorelin is not an FDA-approved drug, but it may be lawfully prepared by a compounding pharmacy for an individual patient with a prescription from a licensed provider.
Status as of July 21, 2026
Gonadorelin is a synthetic copy of gonadotropin-releasing hormone (GnRH), the decapeptide the hypothalamus secretes to run the reproductive axis, and it works by binding GnRH receptors on the pituitary's gonadotroph cells to trigger release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Its defining pharmacologic feature, established in human clinical use, is that the direction of its effect is set by delivery timing rather than dose: brief pulses sustain gonadotropin release, while continuous exposure suppresses it. Because the peptide is degraded by peptidases within minutes, it is administered parenterally rather than orally.
Gonadorelin reproduces the hypothalamic GnRH signal at the pituitary, stimulating LH and FSH release when delivered in roughly 90-minute pulses and suppressing it when delivered continuously.
Gonadorelin's structure is not an engineered analog but the native hormone reproduced by synthesis: a linear chain of ten amino acids whose sequence matches naturally occurring GnRH exactly. The two end modifications, a pyroglutamate ring at the amino terminus and an amidated carboxyl terminus, shape the folded conformation the peptide adopts when it docks into the receptor. Because it carries no protective substitutions, the chain is readily cleaved by endopeptidases, which is the structural reason for its very short duration of action.
Gonadorelin is a linear decapeptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, identical to endogenous GnRH, making it the native hormone rather than an engineered analog.
The GnRH receptor is a seven-transmembrane G protein-coupled receptor on pituitary gonadotrophs, and the mammalian version has a distinctive quirk: it lacks the intracellular carboxyl-terminal tail found on most such receptors. That missing tail slows the internalization and desensitization machinery, which is part of why the receptor tolerates repeated pulsatile stimulation. A single binding event produces both an immediate secretory burst and a slower transcriptional response that refills the cell's hormone stores.
The pituitary GnRH receptor couples through the Gq/11 and phospholipase C pathway, and the resulting rise in intracellular calcium is the immediate trigger for LH and FSH secretion.
The opposite outcomes of the two schedules trace to how the GnRH receptor behaves under intermittent versus uninterrupted stimulation. Continuous exposure first produces a flare of gonadotropin release, then within days downregulates receptor numbers and desensitizes the survivors, collapsing LH and FSH output. Pulsatile delivery imitates the hypothalamus's own roughly 60-to-90-minute bursts, giving the receptor a quiet interval to reset between pulses so secretion is sustained.
| Criterion | Pulsatile delivery | Continuous exposure |
|---|---|---|
| Receptor state | Resets and recycles between pulses | Downregulates and desensitizes |
| LH/FSH output | Sustained secretion | Initial flare, then suppression |
| Axis effect | Drives fertility and sex-steroid output | Reversible chemical shutdown |
| Clinical application | Programmable-pump therapy to restore the axis | Long-acting analogs to lower sex hormones |
Timing, not dose, flips the effect, since pulses roughly every 60 to 90 minutes sustain LH and FSH secretion while continuous exposure downregulates and desensitizes the receptor to suppress the axis.
Gonadorelin's direct output is the two gonadotropins, luteinizing hormone and follicle-stimulating hormone, both glycoprotein hormones sharing a common alpha subunit and differing in their hormone-specific beta subunit. The pulse frequency tunes the ratio between them: faster pulses favor LH synthesis, and slower pulses shift the balance toward FSH. The sex steroids and gametes that follow are second-order consequences, produced only after LH and FSH reach the gonads.
Gonadorelin causes the pituitary to release luteinizing hormone and follicle-stimulating hormone, with measurable serum increases appearing within minutes and peaking near 30 to 45 minutes after an intravenous dose.
The hypothalamic-pituitary-gonadal axis is a three-tier control loop, and gonadorelin operates at its very top by standing in for the hypothalamic signal itself. In healthy physiology the loop is self-regulating: circulating testosterone, estradiol, and progesterone feed back to restrain further GnRH and gonadotropin release, and the ovarian peptide inhibin selectively dampens FSH. The one exception is the positive feedback of rising estradiol late in the follicular phase, which amplifies the pituitary response and produces the ovulatory LH surge.
Within the hypothalamic-pituitary-gonadal axis, gonadorelin acts as an exogenous stand-in for the hypothalamic pulse generator, which is why it can drive the axis in people whose own GnRH secretion is absent or inadequate.
Gonadorelin clears from circulation within minutes, with a plasma half-life on the order of two to four minutes after intravenous dosing. Peptidases in plasma, hypothalamic and pituitary tissue, the kidneys, and the liver cleave the chain at internal bonds, especially around residues five through seven, leaving only short inactive fragments and free amino acids. That brisk elimination is a direct consequence of the unmodified natural sequence carrying no substitutions to shield it from enzymatic attack.
Gonadorelin has a plasma half-life of roughly two to four minutes and is degraded by peptidases into inactive fragments with no long-lived active metabolite, which is why it cannot be dosed once daily.
Both the route and the timing of gonadorelin are decisive, because the peptide survives only briefly in the body. It is administered parenterally, most often intravenously or subcutaneously, since oral dosing would expose it to digestive proteases and first-pass metabolism that destroy it before it reaches the pituitary. The dosing interval, more than the absolute amount, sets the outcome, which is why the same molecule can be made to stimulate or to suppress purely through the rhythm of delivery.
Gonadorelin's route and dosing interval determine its effect, with pulsatile pump delivery roughly every 90 minutes sustaining the axis and a single intravenous bolus serving diagnostic testing of pituitary reserve.
Educational use only. This article describes what the published scientific and clinical literature reports about Gonadorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
